NO20090053L - Metoder for behandling av cancer ved anvendelse av TAK1 inhibitorer - Google Patents
Metoder for behandling av cancer ved anvendelse av TAK1 inhibitorerInfo
- Publication number
- NO20090053L NO20090053L NO20090053A NO20090053A NO20090053L NO 20090053 L NO20090053 L NO 20090053L NO 20090053 A NO20090053 A NO 20090053A NO 20090053 A NO20090053 A NO 20090053A NO 20090053 L NO20090053 L NO 20090053L
- Authority
- NO
- Norway
- Prior art keywords
- cancer
- treatment
- methods
- tak1 inhibitors
- tak1
- Prior art date
Links
- 102100026888 Mitogen-activated protein kinase kinase kinase 7 Human genes 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 108091008743 testicular receptors 4 Proteins 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000019420 lymphoid neoplasm Diseases 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80684506P | 2006-07-10 | 2006-07-10 | |
| PCT/GB2007/002568 WO2008007072A2 (fr) | 2006-07-10 | 2007-07-10 | Procédé d'inhibition cellulaire |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20090053L true NO20090053L (no) | 2009-02-06 |
Family
ID=38920633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20090053A NO20090053L (no) | 2006-07-10 | 2009-01-06 | Metoder for behandling av cancer ved anvendelse av TAK1 inhibitorer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20090312396A1 (fr) |
| EP (1) | EP2041303A2 (fr) |
| JP (1) | JP2009544583A (fr) |
| KR (1) | KR20090027735A (fr) |
| CN (1) | CN101490279A (fr) |
| AU (1) | AU2007274055A1 (fr) |
| BR (1) | BRPI0714158A2 (fr) |
| CA (1) | CA2658163A1 (fr) |
| IL (1) | IL196208A0 (fr) |
| MX (1) | MX2009000376A (fr) |
| NO (1) | NO20090053L (fr) |
| WO (1) | WO2008007072A2 (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9101559B2 (en) * | 2009-05-08 | 2015-08-11 | New York University | Leukemic cell CNS infiltration controlled by notch-induced chemotaxis |
| GB0918579D0 (en) | 2009-10-22 | 2009-12-09 | Imp Innovations Ltd | Gadd45beta targeting agents |
| CN101968491A (zh) * | 2010-09-29 | 2011-02-09 | 上海生物芯片有限公司 | 弥漫性大b细胞淋巴瘤分子病理分型方法及试剂盒和应用 |
| GB201107118D0 (en) * | 2011-04-27 | 2011-06-08 | Imp Innovations Ltd | Method of diagnosis and prognosis |
| WO2012166722A1 (fr) * | 2011-06-03 | 2012-12-06 | The General Hospital Corporation | Traitement du cancer colorectal, pancréatique et pulmonaire |
| WO2013012998A1 (fr) | 2011-07-19 | 2013-01-24 | Emory University | Inhibiteurs de kinase tak1, compositions et utilisations associées |
| EP3079682A4 (fr) | 2013-12-13 | 2017-08-30 | Dana-Farber Cancer Institute, Inc. | Procédé pour traiter un lymphome lymphoplasmocytaire |
| AU2014361798B2 (en) | 2013-12-13 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| EP3715346B1 (fr) | 2014-10-22 | 2024-01-03 | Dana-Farber Cancer Institute, Inc. | Composés contenant des groupes thiazolyle pour le traitement de maladies prolifératives |
| CN104911183B (zh) * | 2015-06-25 | 2018-01-09 | 中山大学孙逸仙纪念医院 | 抑制胰腺癌TAK1基因表达的shRNA的转录模板 |
| WO2018060452A1 (fr) * | 2016-09-30 | 2018-04-05 | Fundació Institut Mar D'investigacions Mèdiques (Imim) | Approches thérapeutiques contre le cancer |
| CN109420170B (zh) | 2017-08-25 | 2021-03-02 | 中国科学院上海营养与健康研究所 | 肿瘤微环境相关靶点tak1及其在抑制肿瘤中的应用 |
| EP4464318A1 (fr) * | 2023-05-19 | 2024-11-20 | Albert-Ludwigs-Universität Freiburg | Ciblage de l'activation de la kinase 1 activée par tgf-b dans le traitement d'états neuro-inflammatoires |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004025362A1 (de) * | 2004-05-19 | 2005-12-22 | Sanofi-Aventis Deutschland Gmbh | Verwendung der TGFbeta-aktivierten Kinase 1 |
| WO2006023210A2 (fr) * | 2004-07-23 | 2006-03-02 | Aveo Pharmaceuticals, Inc. | Gene gp132: techniques et compositions de traitement du cancer |
| WO2007044571A2 (fr) * | 2005-10-06 | 2007-04-19 | President And Fellows Of Harvard College | Procedes permettant d'identifier des proteines essentielles a la proliferation des cellules humaines, et agents therapeutiques diriges contre ces proteines |
-
2006
- 2006-07-10 US US12/373,001 patent/US20090312396A1/en not_active Abandoned
-
2007
- 2007-07-10 EP EP07733507A patent/EP2041303A2/fr not_active Withdrawn
- 2007-07-10 WO PCT/GB2007/002568 patent/WO2008007072A2/fr not_active Ceased
- 2007-07-10 JP JP2009518953A patent/JP2009544583A/ja not_active Withdrawn
- 2007-07-10 BR BRPI0714158-0A patent/BRPI0714158A2/pt not_active IP Right Cessation
- 2007-07-10 CN CNA2007800263166A patent/CN101490279A/zh active Pending
- 2007-07-10 AU AU2007274055A patent/AU2007274055A1/en not_active Abandoned
- 2007-07-10 MX MX2009000376A patent/MX2009000376A/es not_active Application Discontinuation
- 2007-07-10 CA CA002658163A patent/CA2658163A1/fr not_active Abandoned
- 2007-07-10 KR KR1020097001202A patent/KR20090027735A/ko not_active Withdrawn
-
2008
- 2008-12-25 IL IL196208A patent/IL196208A0/en unknown
-
2009
- 2009-01-06 NO NO20090053A patent/NO20090053L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2041303A2 (fr) | 2009-04-01 |
| BRPI0714158A2 (pt) | 2012-12-25 |
| WO2008007072A8 (fr) | 2009-02-26 |
| CA2658163A1 (fr) | 2008-01-17 |
| KR20090027735A (ko) | 2009-03-17 |
| WO2008007072A3 (fr) | 2008-05-08 |
| CN101490279A (zh) | 2009-07-22 |
| MX2009000376A (es) | 2009-03-09 |
| WO2008007072A2 (fr) | 2008-01-17 |
| IL196208A0 (en) | 2009-09-22 |
| AU2007274055A1 (en) | 2008-01-17 |
| JP2009544583A (ja) | 2009-12-17 |
| US20090312396A1 (en) | 2009-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20090053L (no) | Metoder for behandling av cancer ved anvendelse av TAK1 inhibitorer | |
| PH12020500203A1 (en) | Identification of lkb1 mutation as a predictive boimarker for sensitivity to tor kinase inhibitors | |
| MX2009008132A (es) | Terapia de combinacion con inhibidores de angiogenesis. | |
| DE602007012677D1 (de) | Verfahren zur behandlung von zellproliferationsstörungen mit pyrimidindiaminverbindungen | |
| EA201890768A2 (ru) | Лечение злокачественной опухоли ингибиторами tor-киназы | |
| EA201270752A1 (ru) | Ингибиторы киназы и способ лечения злокачественной опухоли с их помощью | |
| EP2331530B8 (fr) | Composés multicycliques fusionnés en tant qu inhibiteurs des protéines kinases | |
| MX2013004086A (es) | Metodos para inhibir proliferacion celular en cancers accionados por egfr. | |
| ES2583010T3 (es) | Nuevos inhibidores de la ruta de Stat3 e inhibidores de células madre del cáncer | |
| WO2012016133A3 (fr) | Inhibiteurs de la ros1 kinase pour le traitement de glioblastome et d'autres cancers déficients en p53 | |
| EA201100125A1 (ru) | Производные пирролопиридинилпиримидин-2-иламина | |
| WO2009134658A3 (fr) | Composés de pyrimidine bicycliques fusionnés en tant qu'inhibiteurs d'aurora kinase | |
| MX2012000709A (es) | Inhibidores de pirrolopiridina de cinasas. | |
| IN2012DN03012A (fr) | ||
| MX2009006542A (es) | Inhibidores de histona desacetilasa y sus profarmacos. | |
| MX2011011735A (es) | Compuestos y metodos para la inhibicion de renina, e indicaciones para ello. | |
| MY147832A (en) | Compounds for enzyme inhibition | |
| GEP20125589B (en) | TRIAZINE COMPOUNDS AS P13 KINASE AND mTOR INHIBITORS | |
| NO20082683L (no) | Neuroendokrin tumorbehandling | |
| GEP20135957B (en) | Heterocyclic compound and usage thereof | |
| MX2010005395A (es) | Metodo para tratar artritis. | |
| WO2010042933A3 (fr) | Inhibition et traitement des métastases du cancer de la prostate | |
| TN2012000205A1 (en) | Method and compositions for treating solid tumors and other malignancies | |
| WO2006055635A3 (fr) | Compositions et methodes de modification de la signalisation autocrine wnt | |
| EA201101041A1 (ru) | Производные пиридазинона |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |